

31. Alford D, Labelle C, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience *Arch Intern Med*. 2011;171(5):425-431. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059544/>. Accessed October 8, 2013.
32. Alford D, Compton P, Samet J. Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy *Ann Intern Med*. 2006;144(2):127-134. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892816/>. .
33. Stephenson D, SAM Committee on Treatment of Opioid Dependence. Draft Guidelines for Physicians Working in California Opioid Treatment Programs 2008. <http://www.csam-asam.org/guideline-physicians-working-california-opioid-treatment-programs>. Accessed December 18, 2013.
34. Weiss RD, Potter JS, Copersino ML, et al. Conducting clinical research with prescription opioid dependence: defining the population *Am J Addict*. 2010;19(2):141-146. [doi:10.1111/j.1521-0391.2009.00017.x](https://doi.org/10.1111/j.1521-0391.2009.00017.x).
35. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card 2015. <http://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGPocketCardStabilizationFinal.pdf> Accessed. Accessed February 21, 2017.
36. Melemis S. Relapse prevention and the five rules of recovery *Yale J Biol Med*. 2015;88:3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553654/>. Accessed April 10, 2018.
37. Nielsen S, Hillhouse M, Thomas C. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users *J Addict Med*. 2013;7(1):33-38. <http://www.ncbi.nlm.nih.gov/pubmed/23222095>. Accessed May 14, 2015.
38. Dunn K, Sigmon S, Strain E. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review *Drug Alcohol Depend*. 2011;119(1-2):1-9. <http://www.ncbi.nlm.nih.gov/pubmed/21741781>. Accessed October 3, 2014.